Uroxatral
Product Images NDC 16590-279

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Uroxatral (NDC 16590-279). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Uroxatral10mg Label)

Uroxatral 10 mg tablet bottle label from Stat Rx USA, containing 30 tablets. The label states it is a generic for alfuzosin HCl extended-release, manufactured by Sanofi-Aventis U.S. LLC. It includes NDC 16590-279-30, dosage and storage instructions, and a drug safety caution highlighted in yellow.*

FDA Label Image

Figure 1 Image (Uroxatral Fig1)

A line graph comparing alfuzosin plasma concentration (ng/ml) over 24 hours under fed versus fasted conditions. The x-axis shows time in hours from 0 to 24, and the y-axis displays plasma concentration from 0 to 14 ng/ml. The fed condition shows higher plasma concentrations with a peak around 10 hours, while the fasted condition remains lower and steadier.*

FDA Label Image

Figure Image 2 (Uroxatral Fig2)

A line graph showing the mean change over days of treatment for Uroxatral and placebo groups. The x-axis represents days of treatment (0, 28, 56, 84), and the y-axis represents mean change. The Uroxatral group shows a greater mean change compared to placebo, with statistical significance (p < 0.001) indicated at day 84.*

FDA Label Image

Figure Image 3 (Uroxatral Fig3)

A line graph comparing mean change over 84 days of treatment between Uroxatral (N=137) and placebo (N=152). The y-axis represents the mean change, and the x-axis represents days of treatment (0, 28, 56, 84). The Uroxatral group shows a greater mean reduction over time compared to placebo, with statistical significance indicated at day 84 (p < 0.01).*

FDA Label Image

Figure Image 4 (Uroxatral Fig4)

A line graph comparing mean change over days of treatment between placebo and Uroxatral groups. The x-axis shows days of treatment (0, 28, 56, 84), and the y-axis shows mean change. Data points for placebo and Uroxatral are marked with triangles and squares respectively, showing a greater decrease in mean change for Uroxatral over time. Statistical significance is indicated for day 84 with a p-value < 0.01.*

FDA Label Image

Figure Image 5 (Uroxatral Fig5)

A line graph comparing the mean change in milliliters per second over 84 days of treatment between Uroxatral (N=170) and placebo (N=167). The graph shows greater improvement with Uroxatral, with notable statistical significance indicated on day 84 (p < 0.001). The x-axis represents days of treatment, and the y-axis represents mean change in mL/s.*

FDA Label Image

Figure Image 6 (Uroxatral Fig6)

A line graph comparing the mean change in mL/s over days of treatment between Uroxatral (N=136) and placebo (N=147). The graph shows higher mean change values for Uroxatral throughout 84 days, with significance indicated at day 84 (p < 0.05).*

FDA Label Image

Figure Image 7 (Uroxatral Fig7)

Line graph comparing mean change in mL/s over days of treatment between Uroxatral (N=151) and placebo (N=150). The x-axis shows days of treatment (0, 14, 28, 56, 84), and the y-axis shows mean change in mL/s from 0 to 3. Uroxatral shows a higher mean change than placebo at all measured times. Statistical notation indicates no significant difference (NS, p > 0.05).*

FDA Label Image

Structure Image (Uroxatral Structure)

Chemical structure of Uroxatral, showing its molecular composition including methoxy groups, amine, and hydrochloride salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.